Welcome to JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION)
Volume 52 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
HAO Xin-yan, ZHANG Yuan-dong, HOU Ying-ying, et al. Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2021, 52(4): 592-597. doi: 10.12182/20210760104
Citation: HAO Xin-yan, ZHANG Yuan-dong, HOU Ying-ying, et al. Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES), 2021, 52(4): 592-597. doi: 10.12182/20210760104

Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery

doi: 10.12182/20210760104
More Information
  • Corresponding author: E–mail: sunxun@scu.edu.cn
  • Received Date: 2021-03-15
  • Rev Recd Date: 2021-06-04
  • Available Online: 2021-07-22
  • Publish Date: 2021-07-22
  •   Objective  To prepare a chitosan-modified cationic nanoemulsion that could be used to prolong the residence time of nasal vaccines in the nasal cavity and improve the cellular uptake efficiency so as to enhance the immune efficacy of nasal vaccines.  Methods  A nanoemulsion-based vaccine coated with chitosan was prepared, and the particle size, potential, antigen encapsulation efficiency, stability as well as cytotoxicity were examined. The uptake efficiency of vaccine on different cells and the residence time of vaccine in the nasal cavity were measured. Finally, nasal vaccine was administered on mice and the antibody levels in the serum and in the nasal lavage fluids of the immunized mice were examined.  Results  The nanoemulsion-based vaccine had an average particle size of (167.2±0.75) nm, a polydispersity index (PDI) of 0.21±0.01, and an average potential of (13.7±0.85) mV. The encapsulation efficiency of antigen was 92.7%. The nanoemulsion-based vaccine had good stability and did not show obvious cytotoxicity in Madin-Darby canine kidney (MDCK) epithelial cells. The vaccine demonstrated relatively high cellular uptake of antigens on DC2.4 and MDCK cells at (49.7±3.45)% and (59.7±2.19)%, respectively. Besides, the cationic nanoemulsion also significantly increased the residence time of the antigen, and a considerable amount of nanoemulsion-based vaccine was found remaining in the nasal cavity 60 minutes after administration. Compared with free antigen and the nanoemulsion without chitosan modification, the chitosan-modified nanoemulsion vaccine induced higher systemic and mucosal antibody levels in mice after nasal immunization (P<0.01).  Conclusion  The chitosan-modified nanoemulsion vaccine prepared in the study can enhance the immune efficacy of nasal vaccines, showing great potential to be used as a delivery carrier for nasal vaccines.
  • loading
  • [1]
    LI M, WANG Y, SUN Y, et al. Mucosal vaccines: Strategies and challenges. Immunol Lett,2020,217: 116–125. doi: 10.1016/j.imlet.2019.10.013
    [2]
    王冰, 刘宏锐, 陈芳, 等. 口腔黏膜给药系统的药物动力学研究进展. 药学学报,2020,55(2): 226–234.
    [3]
    LOBAINA MATO Y. Nasal route for vaccine and drug delivery: Features and current opportunities. Int J Pharm, 2019, 572: 118813 [2021-03-15]. https://doi.org/10.1016/j.ijpharm.2019.118813.
    [4]
    BOYAKA P N. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J Immunol,2017,199(1): 9–16. doi: 10.4049/jimmunol.1601775
    [5]
    欧歌, 马金秋, 朱林, 等. 三磷酸腺苷脂质体鼻用凝胶制备及其抗缺氧作用. 药学学报,2020,55(6): 1288–1295.
    [6]
    JIN Z, GAO S, CUI X, et al. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Int J Pharm, 2019, 572: 118731[2021-03-15]. https://doi.org/10.1016/j.ijpharm.2019.118731.
    [7]
    范雪莲, 徐月桦, 陈刚. 氟化超支化聚酰胺-胺作为流感DNA疫苗递送载体的研究. 药学学报,2020,55(6): 1282–1287.
    [8]
    BERNOCCHI B, CARPENTIER R, BETBEDER D. Nasal nanovaccines. Int J Pharm,2017,530(1/2): 128–138. doi: 10.1016/j.ijpharm.2017.07.012
    [9]
    BRITO L A, CHAN M, SHAW C A, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther,2014,22(12): 2118–2129. doi: 10.1038/mt.2014.133
    [10]
    KO E J, KANG S M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother,2018,14(12): 3041–3045. doi: 10.1080/21645515.2018.1495301
    [11]
    SHIM S, YOO H S. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar Drugs,2020,18(12): 605. doi: 10.3390/md18120605
    [12]
    BRUINSMANN F A, PIGANA S, AGUIRRE T, et al. Chitosan-coated nanoparticles: Effect of chitosan molecular weight on nasal transmucosal delivery. Pharmaceutics,2019,11(2): 86. doi: 10.3390/pharmaceutics11020086
    [13]
    CHRISTENSEN D, BOLLEHUUS HANSEN L, LEBOUX R, et al. A liposome-based adjuvant containing two delivery systems with the ability to induce mucosal immunoglobulin A following a parenteral immunization. ACS Nano,2019,13(2): 1116–1126. doi: 10.1021/acsnano.8b05209
    [14]
    LI J, DIAZ-AREVALO D, CHEN Y, et al. Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza. Front Immunol, 2015, 6: 170[2021-03-15]. https://doi.org/10.3389/fimmu.2015.00170.
    [15]
    KUMAR P, NAGARAJAN A, UCHIL P D. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc,2018,2018(6): 469–471. doi: 10.1101/pdb.prot095505
    [16]
    LI M, ZHAO M, FU Y, et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release,2016,228: 9–19. doi: 10.1016/j.jconrel.2016.02.043
    [17]
    DI COLA E, CANTU L, BROCCA P, et al. Novel O/W nanoemulsions for nasal administration: Structural hints in the selection of performing vehicles with enhanced mucopenetration. Colloids Surf B Biointerfaces, 2019, 183: 110439[2021-03-15]. https://doi.org/10.1016/j.colsurfb.2019.110439.
    [18]
    JIANG Y, LI M, ZHANG Z, et al. Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants. Pharm Res,2014,31(10): 2748–2761. doi: 10.1007/s11095-014-1372-9
    [19]
    LI M, LI Y, PENG K, et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater,2017,64: 237–248. doi: 10.1016/j.actbio.2017.10.019
    [20]
    MORAN H B T, TURLEY J L, ANDERSSON M, et al. Immunomodulatory properties of chitosan polymers. Biomaterials,2018,184: 1–9. doi: 10.1016/j.biomaterials.2018.08.054
    [21]
    LI D, FU D, KANG H, et al. Advances and potential applications of chitosan nanoparticles as a delivery carrier for the mucosal immunity of vaccine. Curr Drug Deliv,2017,14(1): 27–35. doi: 10.2174/1567201813666160804121123
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)

    Article views (542) PDF downloads(65) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return